Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed director
Inv. presentation

BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/20/2021 GN BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
03/10/2021 GN BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
02/17/2021 GN BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
11/20/2020 GN BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
11/11/2020 GN BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18
11/05/2020 GN BioDelivery Sciences Reports Strong Q3 2020 Results
11/04/2020 GN BioDelivery Sciences Announces $25 Million Share Repurchase Program
11/04/2020 GN BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO
10/23/2020 GN BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020
09/11/2020 GN BioDelivery Sciences Announces Five Scientific Poster Presentations at PAINWeek® 2020 National Conference on Pain Management
08/05/2020 GN BioDelivery Sciences Reports Strong Q2 2020 Results
05/29/2020 GN BioDelivery Sciences to Present at Two Upcoming Investor Conferences
05/11/2020 GN BioDelivery Sciences Appoints Jeff Bailey Interim CEO
04/28/2020 GN BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020
02/27/2020 GN BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine's 36th Annual Meeting
01/06/2020 GN BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development
12/19/2019 GN BioDelivery Sciences Added to NASDAQ Biotechnology Index
11/27/2019 GN BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
11/25/2019 GN BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors
11/12/2019 GN BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations
10/01/2019 GN BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
09/17/2019 GN BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
08/29/2019 GN BioDelivery Sciences Announces Upcoming Investor Conference Presentations
08/28/2019 GN BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
07/30/2019 GN BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
06/24/2019 GN BioDelivery Sciences Expands Upon Report from Pain Management Task Force
06/20/2019 GN BioDelivery Sciences Named to the Russell 3000® Index
05/29/2019 GN BioDelivery Sciences Announces Upcoming Investor Conference Presentations
05/28/2019 GN BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
04/11/2019 GN BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock
04/10/2019 GN BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
04/10/2019 GN BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
02/19/2019 GN Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economic Growth
02/04/2019 GN BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy